A Stable Glucagon Analog Administered by a Bihormonal Closed Loop System; a Feasibility Study
The main objective is to determine the feasibility of dasiglucagon in a bi-hormonal reactive closed loop system for automated glucose regulation (artificial pancreas; AP®) in patients with diabetes mellitus type 1. Safety parameters and pharmacodynamics are compared between Dasiglucagon and GlucaGen®.
This study is a single-center, double-blinded, randomized, cross over trial in 12 subjects. The subjects will be randomized to receive either dasiglucagon or GlucaGen® for the first three day study period and switch to the alternate treatment after a wash-out treatment.
/ RecruitingNot ApplicableIIT Dual Hormone Closed Loop in Type 1 Diabetes: a Randomized Trial (DARE)
This study is a 12 month open-label, two-arm randomised parallel-group trial in adult type 1 diabetes patients executed in 14 centres in the Netherlands. The aim of this study is to determine the long-term clinical effectiveness of treatment with a dual-hormone (insulin and glucagon) fully closed loop system during 12 months compared to the current most used care and to the currently most advanced technological care. Secondary objectives include the assessment of cost-effectiveness, Patient Reported Outcome Measures (PROMs), other glycaemic outcomes and safety.
/ CompletedNot Applicable Portable Artificial Pancreas Applied for Youth and Adolescents, PAPAYA 1 - PAPAYA 1
100 Clinical Results associated with Inreda Diabetic BV
0 Patents (Medical) associated with Inreda Diabetic BV
100 Deals associated with Inreda Diabetic BV
100 Translational Medicine associated with Inreda Diabetic BV